Cargando…

Chaperonin‐containing tailless complex polypeptide 1 subunit 6A correlates with increased World Health Organization grade, less isocitrate dehydrogenase mutation, and deteriorative survival of astrocytoma patients

OBJECTIVE: Chaperonin‐containing tailless complex polypeptide 1 subunit 6A (CCT6A) is reported to be an efficient prognostic biomarker in various cancers, but it is rarely reported in astrocytoma. Thus, this study aimed to evaluate the expression of CCT6A and its correlation with disease features an...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Yueyun, Fu, Peng, Zhao, Hongyang, Zhang, Fangcheng, Jiang, Xiaobing, Zhao, Wohua, Lv, Peng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8418478/
https://www.ncbi.nlm.nih.gov/pubmed/34312925
http://dx.doi.org/10.1002/jcla.23917
_version_ 1783748577813594112
author Hu, Yueyun
Fu, Peng
Zhao, Hongyang
Zhang, Fangcheng
Jiang, Xiaobing
Zhao, Wohua
Lv, Peng
author_facet Hu, Yueyun
Fu, Peng
Zhao, Hongyang
Zhang, Fangcheng
Jiang, Xiaobing
Zhao, Wohua
Lv, Peng
author_sort Hu, Yueyun
collection PubMed
description OBJECTIVE: Chaperonin‐containing tailless complex polypeptide 1 subunit 6A (CCT6A) is reported to be an efficient prognostic biomarker in various cancers, but it is rarely reported in astrocytoma. Thus, this study aimed to evaluate the expression of CCT6A and its correlation with disease features and prognosis in astrocytoma patients. METHODS: Totally, 198 astrocytoma patients who received surgery treatment were enrolled. CCT6A protein expression was determined in the tumor tissues fixed in formalin and embedded in paraffin (FFEP) by immunohistochemistry (IHC) assay. In addition, 133 out of 198 astrocytoma patients had fresh tumor tissues frozen in the liquid nitrogen for the determination of CCT6A mRNA expression by reverse transcription‐quantitative polymerase chain reaction. RESULTS: Sixty‐nine (34.8%), 70 (35.4%), 46 (23.2%), and 13 (6.6%) astrocytoma patients had the CCT6A immunohistochemistry (IHC) score of 0–3, 4–6, 7–9, and 10–12, respectively. CCT6A protein expression was correlated with increased World Health Organization (WHO) grade (P < 0.001) and less isocitrate dehydrogenase (IDH) mutation (P = 0.002); meanwhile, CCT6A mRNA expression was only related to elevated WHO grade (P = 0.001). However, CCT6A protein and mRNA expression were not correlated with other clinical features and subsequent treatment modalities (all P > 0.05). Moreover, CCT6A protein high and CCT6A mRNA high were related to shorter accumulating overall survival (OS; both P < 0.05). CCT6A protein high was an independent factor for predicting the worse OS (hazard ratio: 1.821, P = 0.012). CONCLUSION: Chaperonin‐containing tailless complex polypeptide 1 subunit 6A correlates with elevated WHO grade and less IDH mutation; besides, CCT6A high expression is independently associated with unfavorable accumulating OS of astrocytoma patients.
format Online
Article
Text
id pubmed-8418478
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-84184782021-09-08 Chaperonin‐containing tailless complex polypeptide 1 subunit 6A correlates with increased World Health Organization grade, less isocitrate dehydrogenase mutation, and deteriorative survival of astrocytoma patients Hu, Yueyun Fu, Peng Zhao, Hongyang Zhang, Fangcheng Jiang, Xiaobing Zhao, Wohua Lv, Peng J Clin Lab Anal Research Articles OBJECTIVE: Chaperonin‐containing tailless complex polypeptide 1 subunit 6A (CCT6A) is reported to be an efficient prognostic biomarker in various cancers, but it is rarely reported in astrocytoma. Thus, this study aimed to evaluate the expression of CCT6A and its correlation with disease features and prognosis in astrocytoma patients. METHODS: Totally, 198 astrocytoma patients who received surgery treatment were enrolled. CCT6A protein expression was determined in the tumor tissues fixed in formalin and embedded in paraffin (FFEP) by immunohistochemistry (IHC) assay. In addition, 133 out of 198 astrocytoma patients had fresh tumor tissues frozen in the liquid nitrogen for the determination of CCT6A mRNA expression by reverse transcription‐quantitative polymerase chain reaction. RESULTS: Sixty‐nine (34.8%), 70 (35.4%), 46 (23.2%), and 13 (6.6%) astrocytoma patients had the CCT6A immunohistochemistry (IHC) score of 0–3, 4–6, 7–9, and 10–12, respectively. CCT6A protein expression was correlated with increased World Health Organization (WHO) grade (P < 0.001) and less isocitrate dehydrogenase (IDH) mutation (P = 0.002); meanwhile, CCT6A mRNA expression was only related to elevated WHO grade (P = 0.001). However, CCT6A protein and mRNA expression were not correlated with other clinical features and subsequent treatment modalities (all P > 0.05). Moreover, CCT6A protein high and CCT6A mRNA high were related to shorter accumulating overall survival (OS; both P < 0.05). CCT6A protein high was an independent factor for predicting the worse OS (hazard ratio: 1.821, P = 0.012). CONCLUSION: Chaperonin‐containing tailless complex polypeptide 1 subunit 6A correlates with elevated WHO grade and less IDH mutation; besides, CCT6A high expression is independently associated with unfavorable accumulating OS of astrocytoma patients. John Wiley and Sons Inc. 2021-07-27 /pmc/articles/PMC8418478/ /pubmed/34312925 http://dx.doi.org/10.1002/jcla.23917 Text en © 2021 The Authors. Journal of Clinical Laboratory Analysis published by Wiley Periodicals LLC. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Research Articles
Hu, Yueyun
Fu, Peng
Zhao, Hongyang
Zhang, Fangcheng
Jiang, Xiaobing
Zhao, Wohua
Lv, Peng
Chaperonin‐containing tailless complex polypeptide 1 subunit 6A correlates with increased World Health Organization grade, less isocitrate dehydrogenase mutation, and deteriorative survival of astrocytoma patients
title Chaperonin‐containing tailless complex polypeptide 1 subunit 6A correlates with increased World Health Organization grade, less isocitrate dehydrogenase mutation, and deteriorative survival of astrocytoma patients
title_full Chaperonin‐containing tailless complex polypeptide 1 subunit 6A correlates with increased World Health Organization grade, less isocitrate dehydrogenase mutation, and deteriorative survival of astrocytoma patients
title_fullStr Chaperonin‐containing tailless complex polypeptide 1 subunit 6A correlates with increased World Health Organization grade, less isocitrate dehydrogenase mutation, and deteriorative survival of astrocytoma patients
title_full_unstemmed Chaperonin‐containing tailless complex polypeptide 1 subunit 6A correlates with increased World Health Organization grade, less isocitrate dehydrogenase mutation, and deteriorative survival of astrocytoma patients
title_short Chaperonin‐containing tailless complex polypeptide 1 subunit 6A correlates with increased World Health Organization grade, less isocitrate dehydrogenase mutation, and deteriorative survival of astrocytoma patients
title_sort chaperonin‐containing tailless complex polypeptide 1 subunit 6a correlates with increased world health organization grade, less isocitrate dehydrogenase mutation, and deteriorative survival of astrocytoma patients
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8418478/
https://www.ncbi.nlm.nih.gov/pubmed/34312925
http://dx.doi.org/10.1002/jcla.23917
work_keys_str_mv AT huyueyun chaperonincontainingtaillesscomplexpolypeptide1subunit6acorrelateswithincreasedworldhealthorganizationgradelessisocitratedehydrogenasemutationanddeteriorativesurvivalofastrocytomapatients
AT fupeng chaperonincontainingtaillesscomplexpolypeptide1subunit6acorrelateswithincreasedworldhealthorganizationgradelessisocitratedehydrogenasemutationanddeteriorativesurvivalofastrocytomapatients
AT zhaohongyang chaperonincontainingtaillesscomplexpolypeptide1subunit6acorrelateswithincreasedworldhealthorganizationgradelessisocitratedehydrogenasemutationanddeteriorativesurvivalofastrocytomapatients
AT zhangfangcheng chaperonincontainingtaillesscomplexpolypeptide1subunit6acorrelateswithincreasedworldhealthorganizationgradelessisocitratedehydrogenasemutationanddeteriorativesurvivalofastrocytomapatients
AT jiangxiaobing chaperonincontainingtaillesscomplexpolypeptide1subunit6acorrelateswithincreasedworldhealthorganizationgradelessisocitratedehydrogenasemutationanddeteriorativesurvivalofastrocytomapatients
AT zhaowohua chaperonincontainingtaillesscomplexpolypeptide1subunit6acorrelateswithincreasedworldhealthorganizationgradelessisocitratedehydrogenasemutationanddeteriorativesurvivalofastrocytomapatients
AT lvpeng chaperonincontainingtaillesscomplexpolypeptide1subunit6acorrelateswithincreasedworldhealthorganizationgradelessisocitratedehydrogenasemutationanddeteriorativesurvivalofastrocytomapatients